Ketamine Routes Compared: IV vs IM vs Intranasal vs Sublingual Troches for Therapy in 2026

Ketamine therapy in 2026 is delivered through four meaningfully different routes, each producing a distinct session profile. Bioavailability spans a 3-fold range across routes: intravenous infusion at 100 percent, intramuscular injection at roughly 93 percent, intranasal esketamine at approximately 48 percent, and sublingual troches around 30 percent (Andrade, 2019, Journal of Clinical Psychiatry). That range alone reshapes peak plasma concentration, dissociative intensity, and clinical supervision requirements across the four routes.

The practical differences group around four axes. Pharmacokinetics: how fast the molecule reaches peak plasma, how deep the dissociation goes, how long the session lasts. Setting: clinic-based versus at-home telehealth, supervised versus self-administered. Cost: 200 dollars at the low end for troches, 885 dollars at the high end for cash-pay esketamine. Evidence base: IV ketamine has the deepest research portfolio for treatment-resistant depression, esketamine has the only FDA approval, IM and sublingual carry off-label use anchored by smaller trials. Choosing a route is a clinical decision shaped by goals and constraints, not a preference question.

This piece walks through the four routes, the head-to-head pharmacology, the clinical-fit implications, and a framework for choosing in 2026. The goal is a comparison built on the actual numbers, with cost, supervision intensity, and integration support included as first-class variables.

The Four-Route Ketamine Comparison Table

The cleanest way to read the comparison is route by route across eight clinical dimensions, because no single axis settles the choice. Bioavailability is the headline metric, but onset, duration, cost, supervision requirements, and FDA status also drive the practical decision. Wilkinson et al. (2021, American Journal of Psychiatry) ketamine-assisted psychotherapy review summarizes the comparative pharmacology that underlies the table below.

The structural takeaway is that the four routes occupy different clinical niches. IV is the reference standard for severe treatment-resistant depression and research protocols. IM is the practical workhorse for community psychiatric clinics. Intranasal esketamine is the insurance-covered, FDA-approved option. Sublingual troches are the accessibility play, lowering the cost-per-session and removing the geographic constraint. None of these is universally better. The right route depends on indication severity, insurance status, and the patient's capacity for at-home work.

What Makes IV Ketamine the Reference Standard?

IV ketamine is the route most clinical research has used, and it remains the comparator against which other routes are measured. The standard antidepressant protocol is 0.5 mg per kilogram of body weight infused over 40 minutes, producing 100 percent bioavailability and a tightly controlled plasma curve. Krystal et al. (2019, Neuron) summarized the mechanistic and clinical case for IV ketamine in treatment-resistant depression, anchoring the rapid-acting antidepressant story now standard in the field.

The controlled curve is the operational advantage of IV. The clinician can titrate the infusion rate in real time, slow it down if dissociation gets too intense, pause it if cardiovascular signs require, and bring the session to a clean close at the 40-minute mark. Onset is 1 to 2 minutes, peak around 15 to 20 minutes in, and the active dissociative window closes shortly after the infusion stops. This precision is part of why IV remains the reference standard for severe treatment-resistant depression and most research protocols.

The downside is access. IV infusion requires a clinic with IV pump infrastructure, a nurse or physician for the duration, and continuous vital sign monitoring. The cost reflects that: 400 to 800 dollars per session in most markets, with a full induction series of six sessions running 2,400 to 4,800 dollars out of pocket. Insurance coverage for IV ketamine remains spotty in 2026 because the off-label status leaves it outside the reimbursement standard that Spravato gained with FDA approval. The full cost breakdown sits in psychedelic therapy cost 2026.

What an IV Ketamine Session Actually Looks Like

The patient arrives at the clinic, gets vital signs taken, and is connected to an IV line in a quiet room with a reclining chair or bed. The infusion starts, dissociation begins within 1 to 2 minutes, and the experience peaks around 15 to 20 minutes in. The room is typically dark or low-light, often with eyeshades and music. A nurse or physician is present throughout. The infusion ends at 40 minutes, residual dissociation fades over the next 15 to 30 minutes, and the patient is discharged once cleared. The preparation work that determines whether the session lands is covered in ketamine therapy preparation.

Why Does IM Ketamine Persist in Psychiatric Clinics?

Intramuscular ketamine offers nearly the bioavailability of IV without the IV pump infrastructure, which is why community psychiatric clinics adopted it widely. IM bioavailability sits around 93 percent according to Andrade (2019, J Clin Psychiatry), with onset at 5 to 10 minutes and active duration of 60 to 90 minutes. The molecule absorbs through the muscle tissue at a slightly slower rate than IV delivers it, but the total systemic exposure is comparable. The trade-off is precision: once the injection is given, the clinician cannot adjust the dose mid-session.

This route fits the practical workflow of psychiatric clinics that operate without infusion suites. The injection takes seconds. The patient lies down or reclines for the next 60 to 90 minutes. The dissociation builds, peaks, and resolves on its own pharmacokinetic curve. A nurse or physician is present for the duration, but the staffing intensity is lower than continuous IV infusion. The cost reflects that lower overhead: 250 to 500 dollars per session in most markets.

IM ketamine also produces a slightly different subjective profile than IV, often described as longer and more contemplative. The peak is less sharp than IV, the resolution is slower, and patients frequently report a more sustained therapeutic window inside the experience. This is anecdotal more than rigorous, but it shows up consistently in clinical reports. Wilkinson et al. (2021) note IM and IV ketamine as comparable in clinical effect for the ketamine-assisted psychotherapy literature, with route choice often driven by clinic infrastructure rather than therapeutic rationale.

How Does Intranasal Esketamine (Spravato) Differ?

Intranasal esketamine is the only FDA-approved ketamine product for treatment-resistant depression, which makes it a structurally different option from the other three routes. Daly et al. (2019, JAMA Psychiatry) reported the Phase 3 trial supporting FDA approval, with significant MADRS reduction at 56 or 84 milligrams twice weekly compared to oral antidepressant plus placebo nasal spray. The FDA approved Spravato in March 2019, and the REMS (Risk Evaluation and Mitigation Strategy) infrastructure built around it shaped how the route operates clinically.

Patients receive the spray at a REMS-certified clinic, take the dose under observation, and remain at the clinic for 2 hours post-dose for monitoring. The bioavailability through nasal absorption is roughly 48 percent, lower than IV or IM but enough to produce reliable antidepressant response at the studied doses. Onset runs 10 to 30 minutes, active duration 40 to 60 minutes, and the dissociative intensity is generally milder than IV at comparable subjective doses. The session is psychiatric, not psychedelic in framing: there is no integration component built into the standard Spravato protocol.

The cost structure also differs from the other routes. Cash prices run 590 to 885 dollars per dose, but Spravato is the only ketamine route with broad insurance coverage in 2026. Insurance copays often run under 100 dollars per session, which makes it the most accessible route for patients with treatment-resistant depression who have insurance and meet the medical criteria. The medication-management considerations around antidepressant interactions are covered in SSRIs and psychedelics.

The Esketamine vs Racemic Ketamine Question

Spravato is esketamine, the isolated S-enantiomer of the racemic ketamine molecule. R-ketamine, the mirror image, is the other half of standard racemic ketamine used in IV, IM, and sublingual routes. The S-enantiomer binds NMDA more tightly, which is why esketamine doses are lower than equivalent racemic doses. The clinical question of whether racemic ketamine or esketamine produces better antidepressant outcomes is unsettled. Krystal et al. (2019, Neuron) note both forms work but may engage subtly different mechanisms, with some evidence the R-enantiomer in racemic ketamine adds a sustained antidepressant component that pure esketamine lacks.

Where Do Sublingual Troches Fit in 2026?

Sublingual ketamine troches are the at-home telehealth route that emerged after COVID-era regulatory changes opened controlled-substance telehealth prescribing. Bioavailability runs around 30 percent according to Andrade (2019, J Clin Psychiatry), and providers such as Mindbloom and Innerwell deliver troches through compounding pharmacies after telehealth psychiatric evaluation. The route lowers cost per session to 200 to 400 dollars as part of monthly packages, and it removes the geographic constraint that limits clinic-based protocols.

The clinical positioning is different from IV or IM. Troches produce lower peak plasma concentrations and a milder dissociative experience than equivalent IV doses, even when total exposure is similar. This is because absorption through the oral mucosa is slower than IV bolus, so the plasma curve is flatter. The session feels less intense, the supervision requirements are lower, and the trade-off is reduced therapeutic ceiling for severe treatment-resistant cases. Telehealth troche protocols typically work better as maintenance dosing or moderate-severity depression than as initial induction for severe cases.

The supervision model also differs. There is no clinician in the room. The patient takes the troche at home, lies down with eyeshades and music, and checks in with a coach or clinician by phone or video either during or after the session. This is reasonable for patients with stable cardiovascular status, no psychotic spectrum history, and the capacity to self-screen. It is not appropriate for patients with active suicidality, severe dissociative disorders, or unstable medical conditions. The integration support, however, is often more built-in than clinic-based routes: scheduled coaching, journal prompts, and structured follow-up are usually part of the monthly package. For the integration mechanics that determine whether the work lands, see ketamine therapy integration.

"The bioavailability spread across ketamine routes is not just a pharmacokinetic curiosity. It maps directly onto clinical supervision intensity, cost, and the depth of dissociation a patient experiences. Choosing a route is mostly choosing a session model, not choosing a drug."

The Compounding and Regulation Picture

Sublingual troches reach patients through compounding pharmacies rather than FDA-approved manufacturer supply, which creates regulatory ambiguity. The DEA tightened controlled-substance telehealth rules in 2024 and 2025, and the rules continue to evolve. Some telehealth providers operate under the public health emergency telemedicine flexibility extensions, others require an initial in-person evaluation followed by ongoing telehealth maintenance. Patients considering this route should verify the provider's licensing status in their state and the prescribing protocol the provider follows. The model is durable in 2026, but the regulatory framework is not static.

How Do You Choose Between Ketamine Routes?

The choice between ketamine routes is rarely about which one is pharmacologically best in the abstract. It is about which route fits the indication, the insurance status, and the patient's capacity for in-person versus at-home work. In practice, three questions usually settle it. What is the indication severity? What is the insurance and cash budget? And what level of supervision and integration support does the patient need?

For severe treatment-resistant depression, IV ketamine or intranasal esketamine remain the defaults. IV has the deepest research base (Wilkinson 2021), Spravato has FDA approval and insurance coverage (Daly 2019). For patients who fail SSRIs and several augmentation strategies, the clinical case for these routes is strong, and the supervised setting fits the severity. The induction series typically runs 6 to 8 sessions over 2 to 4 weeks, followed by a maintenance plan calibrated to the response.

For moderate-severity depression, anxiety, or patients who want to combine ketamine with active integration work, IM ketamine at a psychiatric clinic offers a middle path. The cost is lower than IV, the experience is slightly more contemplative, and many clinics that offer IM ketamine also incorporate ketamine-assisted psychotherapy in the Wilkinson 2021 framework. For patients who cannot access a local ketamine clinic, sublingual troches through licensed telehealth providers remain a credible option, especially for maintenance work or moderate cases.

The fourth factor is integration. IV and esketamine protocols often have minimal built-in integration. IM clinics vary widely. Telehealth sublingual programs typically have the most structured integration support built into the package, with scheduled coaching calls, journal prompts, and follow-up. The ketamine therapy integration piece covers the post-session work in detail. For patients who plan to do active therapeutic work between sessions, the integration model can matter as much as the route itself.

The Cost and Access Reality in 2026

Cash-pay costs run from 200 dollars per session for sublingual troches to 800 dollars for IV ketamine, with esketamine sitting in the upper range at 590 to 885 dollars cash. Insurance coverage shifts the comparison sharply: Spravato is broadly covered with copays often under 100 dollars per session, while IV and IM ketamine usually require full out-of-pocket payment. Telehealth sublingual programs typically charge monthly packages of 200 to 500 dollars covering 4 to 6 sessions plus integration support. For most patients without insurance coverage for Spravato, telehealth troches are the lowest-cost entry point, with IM ketamine as the middle option and IV at the upper end.

Frequently Asked Questions About Ketamine Routes